Digest Network Come funziona
Network
/
Società
Mi
Non verificato

Mirum Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieMercato azionarioSalute

72 comunicati stampa

Guarda tutti i comunicati
03/05/2026
Telefonia e Varie
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/04/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/04/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/04/2026
Mercato del lavoro
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
16/03/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/03/2026
Mercato azionario
Finanza
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/03/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Eventi
Web e Social Network
Salute
Farmaceutica
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0